COVID-19 (Coronavirus) Update: Testing and Information | Vaccine Updates | Visitor Guidelines

A Phase 3 Multicenter, Double-Blind, Placebo-Controlled Trial of Viralym-M (ALVR105) for the Treatment of Patients With Virus-Associated Hemorrhagic Cystitis After Allogeneic Hematopoietic Cell Transplant.

Protocol No
ALLOVIR-AVM-003-HC
Principal Investigator
Mehdi Hamadani
Phase
III
Summary
The purpose of this study is to determine if ALVR105 is safe and a good treatment for Hemorrhagic Cystitis
Description
Trial of Viralym-M (ALVR105) for Patients With Virus-Associated Hemorrhagic Cystitis after allo-HCT
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL